Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China

Caijun Sun, Yinfeng Zhang, Liqiang Feng, Weiqi Pan, Maochao Zhang, Zheyu Hong, Xin Ma, Xiaoping Chen, Ling Chen

Research output: Contribution to journalArticle

Abstract

Recombinant adenovirus serotype 5 (Ad5) viruses have been extensively explored as vectors for vaccination or gene therapy. However, one major obstacle to their clinical application is the high prevalence of preexisting anti-Ad5 immunity resulting from natural infection. It has been reported that there are geographic variations in the prevalence of natural adenovirus infection. In the present study, we investigated the seroprevalence of Ad5 in Guangzhou, southern China by measuring the Ad5 neutralizing antibodies in blood samples collected from several sites. The seroprevalence was 77.34% in the general healthy population. The seroprevalence and antibody titers increased with age, with the older population (41-72 years old) having the highest seropositivity (84.8%) and percentage (54.4%) of high Ad5 neutralizing antibody titers (>1000). The dynamics of Ad5 neutralizing antibodies were stable and persistent over the course of eight months. Furthermore, the seroprevalence of Ad5 in the HIV-infected AIDS patients was investigated and there was no significant difference from the general healthy population. Our survey provides useful insights for the future development of Ad5-based vaccination and gene therapy.

Original languageEnglish (US)
Pages (from-to)3837-3841
Number of pages5
JournalVaccine
Volume29
Issue number22
DOIs
StatePublished - May 17 2011
Externally publishedYes

Fingerprint

Adenoviridae
Neutralizing Antibodies
neutralizing antibodies
epidemiology
China
serotypes
Acquired Immunodeficiency Syndrome
Epidemiology
seroprevalence
Seroepidemiologic Studies
gene therapy
Genetic Therapy
Vaccination
vaccination
Population
Adenoviridae Infections
Serogroup
geographical variation
Innate Immunity
immunity

Keywords

  • Adenovirus
  • AIDS
  • Antibody
  • HIV, vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. / Sun, Caijun; Zhang, Yinfeng; Feng, Liqiang; Pan, Weiqi; Zhang, Maochao; Hong, Zheyu; Ma, Xin; Chen, Xiaoping; Chen, Ling.

In: Vaccine, Vol. 29, No. 22, 17.05.2011, p. 3837-3841.

Research output: Contribution to journalArticle

Sun, Caijun ; Zhang, Yinfeng ; Feng, Liqiang ; Pan, Weiqi ; Zhang, Maochao ; Hong, Zheyu ; Ma, Xin ; Chen, Xiaoping ; Chen, Ling. / Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. In: Vaccine. 2011 ; Vol. 29, No. 22. pp. 3837-3841.
@article{5644f58762a04eafa4252244662ea3b4,
title = "Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China",
abstract = "Recombinant adenovirus serotype 5 (Ad5) viruses have been extensively explored as vectors for vaccination or gene therapy. However, one major obstacle to their clinical application is the high prevalence of preexisting anti-Ad5 immunity resulting from natural infection. It has been reported that there are geographic variations in the prevalence of natural adenovirus infection. In the present study, we investigated the seroprevalence of Ad5 in Guangzhou, southern China by measuring the Ad5 neutralizing antibodies in blood samples collected from several sites. The seroprevalence was 77.34{\%} in the general healthy population. The seroprevalence and antibody titers increased with age, with the older population (41-72 years old) having the highest seropositivity (84.8{\%}) and percentage (54.4{\%}) of high Ad5 neutralizing antibody titers (>1000). The dynamics of Ad5 neutralizing antibodies were stable and persistent over the course of eight months. Furthermore, the seroprevalence of Ad5 in the HIV-infected AIDS patients was investigated and there was no significant difference from the general healthy population. Our survey provides useful insights for the future development of Ad5-based vaccination and gene therapy.",
keywords = "Adenovirus, AIDS, Antibody, HIV, vaccine",
author = "Caijun Sun and Yinfeng Zhang and Liqiang Feng and Weiqi Pan and Maochao Zhang and Zheyu Hong and Xin Ma and Xiaoping Chen and Ling Chen",
year = "2011",
month = "5",
day = "17",
doi = "10.1016/j.vaccine.2011.03.042",
language = "English (US)",
volume = "29",
pages = "3837--3841",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "22",

}

TY - JOUR

T1 - Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China

AU - Sun, Caijun

AU - Zhang, Yinfeng

AU - Feng, Liqiang

AU - Pan, Weiqi

AU - Zhang, Maochao

AU - Hong, Zheyu

AU - Ma, Xin

AU - Chen, Xiaoping

AU - Chen, Ling

PY - 2011/5/17

Y1 - 2011/5/17

N2 - Recombinant adenovirus serotype 5 (Ad5) viruses have been extensively explored as vectors for vaccination or gene therapy. However, one major obstacle to their clinical application is the high prevalence of preexisting anti-Ad5 immunity resulting from natural infection. It has been reported that there are geographic variations in the prevalence of natural adenovirus infection. In the present study, we investigated the seroprevalence of Ad5 in Guangzhou, southern China by measuring the Ad5 neutralizing antibodies in blood samples collected from several sites. The seroprevalence was 77.34% in the general healthy population. The seroprevalence and antibody titers increased with age, with the older population (41-72 years old) having the highest seropositivity (84.8%) and percentage (54.4%) of high Ad5 neutralizing antibody titers (>1000). The dynamics of Ad5 neutralizing antibodies were stable and persistent over the course of eight months. Furthermore, the seroprevalence of Ad5 in the HIV-infected AIDS patients was investigated and there was no significant difference from the general healthy population. Our survey provides useful insights for the future development of Ad5-based vaccination and gene therapy.

AB - Recombinant adenovirus serotype 5 (Ad5) viruses have been extensively explored as vectors for vaccination or gene therapy. However, one major obstacle to their clinical application is the high prevalence of preexisting anti-Ad5 immunity resulting from natural infection. It has been reported that there are geographic variations in the prevalence of natural adenovirus infection. In the present study, we investigated the seroprevalence of Ad5 in Guangzhou, southern China by measuring the Ad5 neutralizing antibodies in blood samples collected from several sites. The seroprevalence was 77.34% in the general healthy population. The seroprevalence and antibody titers increased with age, with the older population (41-72 years old) having the highest seropositivity (84.8%) and percentage (54.4%) of high Ad5 neutralizing antibody titers (>1000). The dynamics of Ad5 neutralizing antibodies were stable and persistent over the course of eight months. Furthermore, the seroprevalence of Ad5 in the HIV-infected AIDS patients was investigated and there was no significant difference from the general healthy population. Our survey provides useful insights for the future development of Ad5-based vaccination and gene therapy.

KW - Adenovirus

KW - AIDS

KW - Antibody

KW - HIV, vaccine

UR - http://www.scopus.com/inward/record.url?scp=80051739655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051739655&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.03.042

DO - 10.1016/j.vaccine.2011.03.042

M3 - Article

C2 - 21447314

AN - SCOPUS:80051739655

VL - 29

SP - 3837

EP - 3841

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 22

ER -